1 results match your criteria Clinical Ovarian Cancer [Journal]
Clin Ovarian Cancer Other Gynecol Malig 2011 Jun;4(1):26-33
Gynecologic Oncology Program, Brigham and Women's Hospital, Boston, MA.
OBJECTIVE: To explore the safety, efficacy, and biomarkers of bevacizumab with gemcitabine and oxaliplatin in women with recurrent platinum-sensitive ovarian carcinoma. METHODS: The patients received bevacizumab (10 mg/kg), gemcitabine (1000 mg/m(2)), and oxaliplatin (65 mg/m(2)) on days 1 and 15 in 28-day cycles. The patients with safely accessible tumor underwent intratumoral fluid pressure (IFP) measurements and positron-emission tomographies immediately and 2 weeks after treatment. Read More
Download full-text PDF